AzTrials
AzTrials

Breast ReconstructionAthenaNCT02724371

A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction

A study testing Mentor Larger Size MemoryGel Ultra High Profile Breast Implant in people with Breast Reconstruction and Revision Breast Reconstruction, run by Mentor Worldwide, LLC at 30 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The study will evaluate the long-term safety and effectiveness with the Mentor MemoryGel® Larger Size Ultra High Profile (UHP-L) Breast Implants. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
30 sitesUnited States
Study dates
1 Apr 2016to 31 Jan 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject is female and is at least 18 years old
  • A candidate for:
  • Primary breast reconstruction in women at least 18 years old with surgically absent breast tissue (two-stage reconstruction [tissue expanders utilized with or without the use of human acellular dermal matrices (ADM), limited to AlloDerm® and FlexHD® PLIABLE, utilized in a prior surgery to expand tissue for study device placement] to replace breast tissue post-mastectomy)
  • Revision surgery in women at least 18 years old with surgically absent breast tissue (previous reconstruction with silicone-filled or saline-filled implants or revision reconstruction requiring expansion surgery prior to surgery for study device implantation, with or without the use of human acellular dermal matrices (ADM), limited to AlloDerm® and FlexHD® PLIABLE, utilized in a prior surgery to expand tissue for study device placement)
  • Subject understands and signs the Informed Consent
  • Subject agrees to return device to Mentor if device is explanted
  • Subject agrees to comply with follow-up procedures, including returning for all follow-up visits
  • Physician determines implant volume appropriate for the patient taking into account the subject's BMI and chest width

Who cannot join

  • Subject is pregnant at time of enrollment
  • Subject is a current smoker, or has smoked within 3 months prior to enrollment, or plans to resume smoking within 3 months post-enrollment
  • Currently has uncontrolled diabetes (at time of screening or enrollment)
  • Has nursed a child within 3 months of study enrollment
  • Confirmed or suspected diagnosis of the following rheumatological autoimmune diseases or immune compromised status: SLE, Sjogren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome
  • Currently has a condition that could compromise or complicate wound healing. Note, obesity alone is not an exclusion. All surgical risk factors (obesity, diabetes, smoking history, and prior radiation) should be considered in totality for proper subject selection
Show all 16Show fewer
  • Infection or abscess anywhere in the body
  • Demonstrates tissue characteristics that are clinically incompatible with successful use of a breast implant (e.g. inadequate tissue or compromised vascularity)
  • Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk
  • Anatomic or physiologic abnormality that could lead to significant postoperative adverse events
  • Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure
  • Untreated active, or inappropriately/inadequately treated breast malignancy, without surgical treatment
  • Anticipated need for use of ADM/mesh at the time of implant or implant exchange
  • Subject is HIV positive
  • Works for Mentor or the study doctor or is directly related to anyone who works for Mentor or the study doctor
  • Implanted metal or metal devices that make a MRI scan prohibitive, history of claustrophobia or other condition that would make a MRI scan prohibitive

Trial locations and contacts

30 sites in 1 country.

30 sites in 1 country

United States30 sites
  • The Center for Dermatology and Plastic Surgery at Springbrook

    Alcoa, Tennessee, 37701

  • Buckhead Plastic Surgery, P.C

    Atlanta, Georgia, 30342

  • Adventist Health Bakersfield

    Bakersfield, California, 93301

  • Paul Glat, MD, PC

    Bala-Cynwyd, Pennsylvania, 19087

  • Susan E Downey MD, Inc

    Burbank, California, 91505

  • Plastic Surgery Institute of Dayton

    Centerville, Ohio, 45458

  • UVA Health System

    Charlottesville, Virginia, 22903

  • The Plastic Surgery Group PC

    Chattanooga, Tennessee, 37403

  • The Plastic Surgery Group

    Cincinnati, Ohio, 45227

  • The Cleveland Clinic

    Cleveland, Ohio, 44195

  • The Ohio State University Plastic Surgery

    Columbus, Ohio, 43212

  • Houston Methodist Hospital

    Houston, Texas, 77030

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa, 52242

  • The University of Kansas

    Kansas City, Kansas, 66160

  • Liu Plastic Surgery

    Los Gatos, California, 95032

  • Abbott Northwestern Hospital

    Minneapolis, Minnesota, 55407

  • The Centre, PC

    Mishawaka, Indiana, 46545

  • Plastic Surgery Associates of Montgomery

    Montgomery, Alabama, 36117

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

  • The Mount Sinai Medical Center

    New York, New York, 10029

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Mosharrafa Plastic Surgery

    Phoenix, Arizona, 85028

  • Mayo Clinic Arizona - Scottsdale/Phoenix (MCSB)

    Phoenix, Arizona, 85054

  • Legacy Good Samaritan Medical Center

    Portland, Oregon, 97210

  • Georgia Institute of Plastic Surgery

    Savannah, Georgia, 31405

  • Andres Plastic Surgery

    Scottsdale, Arizona, 85260

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • Stanford University School of Medicine

    Stanford, California, 94305

  • Baylor Scott & White Health

    Temple, Texas, 76508

Other trials in United States

About this study

Official title: Post-Approval Study of the Safety and Effectiveness of the Mentor Smooth Larger Size MemoryGel Ultra High Profile (UHP-L) Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction

The study will evaluate the long-term safety and effectiveness with the Mentor MemoryGel® Larger Size Ultra High Profile (UHP-L) Breast Implants.

Read the detailed description

Subjects, whose body shape is suited to a larger size implant than are currently available, will have their breasts reconstructed using the UHP-L Breast Implants either for the first time after a full mastectomy or as a revision of a previous breast reconstruction.

Being tested
Mentor Larger Size MemoryGel Ultra High Profile Breast Implant

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mentor Larger Size MemoryGel Ultra High Profile Breast ImplantDevice

    Also called UHP-L Breast Implant

    The Mentor smooth larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.

Study groups in NCT02724371
Study groupRoleWhat they receive
Primary Breast ReconstructionExperimentalParticipants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
Receives: Device: Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
Revision Breast ReconstructionExperimentalParticipants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
Receives: Device: Mentor Larger Size MemoryGel Ultra High Profile Breast Implant

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation

    Measured: 10 years

  2. 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Baker III, IV Capsular Contracture

    Measured: 10 year

  3. 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Infection

    Measured: 10 year

  4. 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Explantation with or without replacement

    Measured: 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Mar 2016 (estimated)
  2. Study start1 Apr 2016
  3. Primary completion31 Jan 2029 (estimated)
  4. Study completion31 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02724371
Sponsor's protocol ID
MEN-15-001
Acronym
Athena
Status last verified
Nov 2026
First submitted
21 Mar 2016
Last updated
3 Nov 2026
Results posted
No
Data monitoring committee
No
Individual data sharing
Yes: The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Questions about this trial

What is this clinical trial studying?

A study testing Mentor Larger Size MemoryGel Ultra High Profile Breast Implant in people with Breast Reconstruction and Revision Breast Reconstruction, run by Mentor Worldwide, LLC at 30 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 30 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation (time frame: 10 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in